The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

Coronavirus Disease 2019 Clinical Trial

Official title:

The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04403009
• Other study ID #: YLS2020(112)
• Status: Completed
• Start date: February 1, 2020
• Est. completion date: June 20, 2020

Study information

• Verified date: March 2023
• Source: The First Affiliated Hospital of Guangzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: June 20, 2020
• Est. primary completion date: June 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 100 Years

Eligibility

Inclusion Criteria:

• The patients with Coronavirus Disease 2019

• Positive result on real-time reverse-transcriptase-polymerase-chain-reaction

• Positive result on chest computed tomography

Exclusion Criteria:

• No

Related Conditions & MeSH terms

• Character of the Severe Patients
• Coronavirus Disease 2019
• Coronavirus Infections
• COVID-19

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Guangzhou Medical University	Guanzhou	Guangdong
China	Hankou Hospital	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	SPO2	oxygen Saturation	2 month
Primary	Lymphocyte cell	the counting of Lymphocyte(counts/L)	2 month
Primary	d-dimer	d-dimer(mg/L)	2 month
Primary	PLT	the counting of Platelets((counts/L))	2 month
Primary	CRP	the level of C-reactive protein (mg/uL)	2 month
Primary	LDH	lactate dehydrogenase ( U/L)	2 month
Primary	CK	creatine kinase (U/L)	2 month
Primary	PT	prothrombin time(second)	2 month
Primary	ALT	alanine aminotransferase(U/L)	2 month
Primary	AST	aspartate aminotransferase(U/L)	2 month
Primary	NK cell	natural killer cell(counts/L)	2 month
Primary	PCT	procalcitonin(ng/ml)	2 month
Primary	IL-6	interleukin-6(mg/L)	2 month
Secondary	the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases	CT scan feature	2 months